The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

XLIII.a

Bronchospasm - Wheezing - Asthma

Publications

Hanania NA, Mannava B, Franklin AE, Lipworth BJ, Williamson PA, Garner WJ, Dickey BF, Bond RA

Response to salbutamol in patients with mild asthma treated with nadolol.

The European respiratory journal 2010 Oct;36;963-5 — 2010 Oct — 963-5

Hanania NA, Singh S, El-Wali R, Flashner M, Franklin AE, Garner WJ, Dickey BF, Parra S, Ruoss S, Shardonofsky F, O'Connor BJ, Page C, Bond RA

The safety and effects of the beta-blocker, nadolol, in mild asthma: an open-label pilot study.

Pulmonary pharmacology & therapeutics 2008;21;134-41 — 2008 — 134-41

Raine JM, Palazzo MG, Kerr JH, Sleight P

Near-fatal bronchospasm after oral nadolol in a young asthmatic and response to ventilation with halothane.

British medical journal (Clinical research ed.) 1981 Feb 14;282;548-9 — 1981 Feb 14 — 548-9